Articles by Faiz Kermani - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Faiz Kermani

Faiz Kermani


Articles
EU and US unite against rare diseases
July 1, 2009

Rare diseases represent an important area of unmet medical need.

The R&D hurdles for neglected diseases
June 1, 2009

Modern medicines have dramatically improved the health of millions of people worldwide, but the healthcare situation in industrialized countries is a stark contrast to that in the least developed countries where neglected diseases are still prevalent.

The FDA's new direction
May 1, 2009

With a new head of the FDA expected to be announced imminently, the pharmaceutical industry waits to witness the changes that will inevitably accompany the new appointment. These changes could, however, also impact the rest of the world's pharmaceutical markets.

Building on the promise of biotech
March 1, 2009

The productivity of the pharma industry has been declining for several years. Could biotechnology reinvigorate drug development?

The tough road for US pharma
January 1, 2009

How will the world's dominant pharmaceutical market fare under the new US president?

All change for drug distribution
November 1, 2008

Together, Europe and the US account for more than 70% of the global pharmaceutical market, and the growth of these markets is heavily dependent on distribution systems.

Regulatory affairs: additional value?
September 1, 2008

All commercial sponsors want to maximize their profit and, with a population close to 500 million, the EU is an enormous potential marketplace that they simply cannot ignore!

New interest in an old market: South Korea
July 1, 2008

Despite high ambitions for its pharmaceutical and biotech sectors, South Korea still faces a number of hurdles against competing internationally.

China captivates the clinical trial sector
May 1, 2008

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here